

**Amendment of the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of claims:**

1. (Currently Amended) A process for extending lifespan of a mouse, a human, or a cell thereof ~~mammal or a mammalian cell~~ beyond a generic expected lifespan for said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ comprising administering to said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ a therapeutically effective amount of a composition comprising a C<sub>60</sub> compound or a combination of such C<sub>60</sub> compounds, said C<sub>60</sub> compounds being selected from the group consisting of *e,e,e* C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>2</sub>(CHCOOH), *e,e,e* C<sub>60</sub>(CHCOOH)<sub>3</sub>, C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>n</sub>, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C<sub>60</sub> moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C<sub>60</sub> moiety, wherein n =1, 2, or 3, and wherein said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~ is not selected for a disability, thereby extending the lifespan of said mouse, said human, or said cell thereof ~~mammal or said mammalian cell~~ beyond the generic expected lifespan for said mouse, said human, or said cell thereof ~~mammal or said mammalian cell~~ by up to about 20% ~~[[32%]]~~.

3. (Previously Presented) The process of Claim 1 wherein said at least one said C<sub>60</sub> compound is administered in a composition further comprising a pharmaceutically acceptable carrier.

4. (Previously Presented) The process of Claim 1 where n is 3.

5. (Previously Presented) The process of Claim 4 wherein said C<sub>60</sub> compound is *e,e,e* C<sub>60</sub>(C(COOH)<sub>2</sub>)<sub>3</sub>.

6. (Previously Presented) The process of Claim 1 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly, subcutaneously or orally.

7. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.

8. (Previously Presented) The process of Claim 7 wherein said C<sub>60</sub> compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.

9. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered orally in an amount of at least 0.1 mg/kg.

10. (Previously Presented) The process of Claim 6 wherein said C<sub>60</sub> compound is administered orally in an amount of about 15 mg/kg.

11. (Previously Presented) The process of Claim 7 wherein said C<sub>60</sub> compound is administered daily.

12. (Previously Presented) The process of Claim 9 wherein said C<sub>60</sub> compound is administered daily.

13.-69. (Canceled)

70. (Currently Amended) The process as set forth in Claim 1 wherein an expected lifespan of said mouse, said human, or said cell thereof ~~the mammal or mammalian cell~~ prior to treatment is the generic expected lifespan for said mouse, said human, or said cell thereof ~~mammal or mammalian cell~~.